Solvay Pharmaceuticals settles lawsuit against Global Pharma, Impax Labs for pseudo-generic products

By Lisa Kerner

Charlotte, N.C., July 12 - Solvay said its U.S. subsidiary, Solvay Pharmaceuticals Inc., has settled a lawsuit filed against Global Pharmaceuticals and Impax Laboratories, Inc. alleging that the companies falsely advertised and marketed their products as generic equivalents to Solvay Pharmaceuticals' Creon Minimicrospheres (Pancrelipase Delayed-release Capsules, USP) for the treatment of pancreatic exocrine insufficiency often associated with cystic fibrosis and chronic pancreatitis.

Under the settlement terms, Global and Impax will pay $23 million to Solvay Pharmaceuticals, with the remaining $11 million paid to Solvay.

In addition, Global and Impax must discontinue current marketing practices that state or imply its products are generic equivalents to Creon brand products and discontinue current product labeling, distribution and sales of Lipram-CR 5, Lipram-CR 10 and Lipram-CR 20.

Solvay Pharmaceuticals is a subsidiary of Solvay, an international chemical and pharmaceutical group based in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.